Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers; prostate, breast, lung, and pancreatic cancers; hepatitis C virus; hepatitis B virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, LLC, The Wistar Institute, University of Pennsylvania, GeneOne Life Science Inc., Regeneron Pharmaceuticals, Inc., Genentech, Inc., Plumbline Life Sciences, Inc., the Parker Institute for Cancer Immunotherapy, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, National Institute of Allergy and Infectious Diseases, United States Military HIV Research Program, U.S. Army Medical Research Institute of Infectious Diseases, National Institutes of Health, HIV Vaccines Trial Network, Defense Advanced Research Projects Agency, and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INO
Previous Symbol
CUSIPN/A
Phone267-440-4200
Debt
Debt-to-Equity RatioN/A
Current Ratio3.34
Quick Ratio3.34
Price-To-Earnings
Trailing P/E Ratio-4.73
Forward P/E Ratio-5.16
P/E GrowthN/A
Sales & Book Value
Annual Sales$42.22 million
Price / Sales11.65
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.58 per share
Price / Book3.27
Profitability
EPS (Most Recent Fiscal Year)($1.09)
Net Income$-88,200,000.00
Net Margins-232.58%
Return on Equity-72.66%
Return on Assets-52.58%
Miscellaneous
Employees280
Outstanding Shares95,350,000
Market Cap$491.99 million
OptionableOptionable
Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Shares of Inovio Pharmaceuticals reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals Inc (NASDAQ:INO) posted its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.05. The biopharmaceutical company earned $2 million during the quarter, compared to analyst estimates of $2.20 million. Inovio Pharmaceuticals had a negative net margin of 232.58% and a negative return on equity of 72.66%. During the same quarter last year, the firm posted ($0.39) EPS. View Inovio Pharmaceuticals' Earnings History.
When is Inovio Pharmaceuticals' next earnings date?
What price target have analysts set for INO?
4 brokerages have issued 1 year price targets for Inovio Pharmaceuticals' stock. Their predictions range from $8.00 to $14.00. On average, they expect Inovio Pharmaceuticals' share price to reach $10.75 in the next year. This suggests a possible upside of 108.3% from the stock's current price. View Analyst Price Targets for Inovio Pharmaceuticals.
What is the consensus analysts' recommendation for Inovio Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inovio Pharmaceuticals.
What are Wall Street analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $1.4B, which includes a discounted cash flow based asset value for 15% discount rate, 2% terminal growth rate and 80% probability of success." (12/5/2018)
- 2. Maxim Group analysts commented, "Inovio announced dosing of the first patient in a P1/2a bladder cancer trial with immunotherapy candidate INO-5401. Partnered with Roche/Genentech (ROG – NR), the triple combo used for dosing includes: INO-5401 (multiple cancer antigens) + INO-9012 (IL-12 stimulator) + Roche’s Tecentriq (PD-L1, atezolizumab)." (8/16/2018)
- 3. According to Zacks Investment Research, "Inovio has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates raises a concern. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. However, Inovio’ progress with its lead pipeline candidate, VGX-3100, for the treatment of cervical dysplasia is encouraging. Additionally, Inovio’s collaboration with big pharma companies namely Regeneron andAstraZeneca as they lend the company with the respective expertise bodes well. Moreover, the company’s targeted cervical cancer market holds untapped potential." (7/3/2018)
Has Inovio Pharmaceuticals been receiving favorable news coverage?
News articles about INO stock have trended positive on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inovio Pharmaceuticals earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), Luminex (LMNX), Nevro (NVRO), AtriCure (ATRC), K2M Group (KTWO), Orthofix Medical (OFIX), Cryolife (CRY), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD), Intersect ENT (XENT), AngioDynamics (ANGO) and SurModics (SRDX).
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Dr. J. Joseph Kim, CEO, Pres & Director (Age 49)
- Mr. Peter D. Kies, Chief Financial Officer (Age 55)
- Dr. Niranjan Y. Sardesai, Chief Operating Officer (Age 50)
- Dr. Mark L. Bagarazzi, Chief Medical Officer (Age 57)
- Ben Matone, Director of Investor Relations
Who are Inovio Pharmaceuticals' major shareholders?
Inovio Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.61%), Wasatch Advisors Inc. (5.21%), Vanguard Group Inc. (4.45%), ARK Investment Management LLC (2.10%), Panagora Asset Management Inc. (0.71%) and Dimensional Fund Advisors LP (0.57%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Peter Kies and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.
Which major investors are selling Inovio Pharmaceuticals stock?
INO stock was sold by a variety of institutional investors in the last quarter, including Virtus ETF Advisers LLC, Morgan Stanley, Levin Capital Strategies L.P. and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jong Joseph Kim, Peter Kies and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.
Which major investors are buying Inovio Pharmaceuticals stock?
INO stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., ARK Investment Management LLC, Dimensional Fund Advisors LP, FMR LLC, Panagora Asset Management Inc., Round Table Services LLC, Vanguard Group Inc. and BlackRock Inc.. View Insider Buying and Selling for Inovio Pharmaceuticals.
How do I buy shares of Inovio Pharmaceuticals?
Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of INO stock can currently be purchased for approximately $5.16.
How big of a company is Inovio Pharmaceuticals?
Inovio Pharmaceuticals has a market capitalization of $491.99 million and generates $42.22 million in revenue each year. The biopharmaceutical company earns $-88,200,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Inovio Pharmaceuticals employs 280 workers across the globe.
What is Inovio Pharmaceuticals' official website?
How can I contact Inovio Pharmaceuticals?
Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]
MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.
